Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis.
axial spondyloarthritis
biomarker
cardiovascular risk
disease severity
irisin
subclinical atherosclerosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
03
2022
accepted:
08
06
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
30
7
2022
Statut:
epublish
Résumé
Patients with axial spondyloarthritis (axSpA) have a high disease burden mainly due to the rheumatic disease itself, and also exhibit accelerated atherosclerosis, that leads to a higher incidence of cardiovascular (CV) disease. Accordingly, the identification of biomarkers of CV risk and inflammation in axSpA patients is clinically relevant. In this sense, given the beneficial functions exerted by the adipomyokine irisin in processes related to CV disease and inflammation, our aim was to assess, for the first time, the role of irisin as a genetic and serological biomarker of subclinical atherosclerosis, CV risk and disease severity in axSpA patients. A large cohort of 725 Spanish patients with axSpA was included. Subclinical atherosclerosis (presence of plaques and abnormal carotid intima-media thickness values) was evaluated by carotid ultrasound. Four Low irisin levels were linked to the presence of plaques (p=0.002) and atherogenic index values ≥4 (p=0.01). Serum irisin were positively correlated with C-peptide levels (p<0.001) and negatively correlated with visual analogue scale and Bath Ankylosing Spondylitis Metrology Index (p<0.05 in all the cases). Moreover, lower irisin levels were observed in patients with sacroiliitis and in those with a negative HLA-B27 status (p<0.001 and p=0.006, respectively), as well as in those treated with non-steroidal anti-inflammatory drugs and conventional disease-modifying antirheumatic drugs (p<0.001 and p=0.002, respectively). Interestingly, the TT genotype and the T allele of rs16835198 were less frequent in axSpA patients with ASDAS >2.1 (Odds Ratio (OR): 0.48 [0.28-0.83] and OR: 0.73 [0.57-0.92], respectively, p=0.01 in both cases). Additionally, the frequency of rs1570569 T allele was higher in these patients (OR: 1.46 [1.08-1.97], p=0.01). Furthermore, the GGGT haplotype was more frequent in patients with ASDAS values >2.1 (OR: 1.73 [1.13-2.66], p=0.01). Our results indicate that low serum irisin levels could be indicators of the presence of subclinical atherosclerosis, high CV risk and more severe disease in axSpA patients. In addition,
Identifiants
pubmed: 35898516
doi: 10.3389/fimmu.2022.894171
pmc: PMC9309281
doi:
Substances chimiques
Fibronectins
0
Genetic Markers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
894171Informations de copyright
Copyright © 2022 Remuzgo-Martínez, Rueda-Gotor, Pulito-Cueto, López-Mejías, Corrales, Lera-Gómez, Pérez-Fernández, Portilla, González-Mazón, Blanco, Expósito, Mata, Llorca, Hernández-Hernández, Rodríguez-Lozano, Barbarroja, Ortega-Castro, Vicente, Fernández-Carballido, Martínez-Vidal, Castro-Corredor, Anino-Fernández, Peiteado, Plasencia-Rodríguez, Galíndez-Agirregoikoa, García-Vivar, Vegas-Revenga, Urionaguena, Gualillo, Quevedo-Abeledo, Castañeda, Ferraz-Amaro, González-Gay and Genre.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Endocrinol (Lausanne). 2021 Jul 01;12:678309
pubmed: 34276559
Int J Mol Sci. 2020 Sep 29;21(19):
pubmed: 33003348
Rheumatology (Oxford). 2018 Aug 1;57(suppl_6):vi29-vi34
pubmed: 30445484
J Transl Med. 2014 Aug 06;12:214
pubmed: 25092442
Biochem Biophys Rep. 2020 Feb 21;22:100742
pubmed: 32123756
Biomed Res Int. 2014;2014:860651
pubmed: 24757680
Korean Circ J. 2017 Jan;47(1):44-49
pubmed: 28154590
Am J Med Sci. 2021 Jul;362(1):63-71
pubmed: 33647285
Front Endocrinol (Lausanne). 2019 Aug 02;10:524
pubmed: 31428053
PLoS One. 2014 Nov 04;9(11):e109957
pubmed: 25369206
PLoS One. 2016 Apr 29;11(4):e0154319
pubmed: 27128661
Immunotargets Ther. 2021 May 03;10:141-153
pubmed: 33977094
Sci Rep. 2020 Jun 15;10(1):9636
pubmed: 32541676
Med Sci Monit. 2016 Nov 05;22:4193-4197
pubmed: 27815563
Ann Rheum Dis. 2009 Jun;68 Suppl 2:ii1-44
pubmed: 19433414
Genet Test Mol Biomarkers. 2016 Feb;20(2):86-9
pubmed: 26625129
Nature. 2012 Jan 11;481(7382):463-8
pubmed: 22237023
Best Pract Res Clin Rheumatol. 2016 Oct;30(5):851-869
pubmed: 27964792
Clin Exp Rheumatol. 2013 Jul-Aug;31(4):612-20
pubmed: 23406817
Sleep Med. 2020 Mar;67:71-76
pubmed: 31918120
Metabolism. 2014 Apr;63(4):574-83
pubmed: 24559842
JACC Cardiovasc Imaging. 2014 Oct;7(10):1025-38
pubmed: 25051948
Acta Pharmacol Sin. 2021 Sep;42(9):1390-1400
pubmed: 33214697
Sci Rep. 2021 Jun 10;11(1):12331
pubmed: 34112886
Semin Arthritis Rheum. 2021 Apr;51(2):395-403
pubmed: 33607385
Medicina (Kaunas). 2019 Aug 15;55(8):
pubmed: 31443222
Protein Pept Lett. 2018;25(6):560-569
pubmed: 29745314
Gene. 2017 Aug 30;626:26-31
pubmed: 28479383
Int J Cardiol. 2018 Sep 15;267:177-182
pubmed: 29859711
J Intern Med. 2017 Jan;281(1):3-6
pubmed: 27995692
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211015034
pubmed: 33983056
Front Med (Lausanne). 2018 Mar 12;5:62
pubmed: 29594122
Endocrine. 2016 Aug;53(2):459-64
pubmed: 26940815
Biochimie. 2019 Mar;158:111-116
pubmed: 30611879
Minerva Endocrinol. 2020 Mar;45(1):61-69
pubmed: 29160049
Int J Endocrinol. 2021 Mar 18;2021:6572342
pubmed: 33790964
J Am Heart Assoc. 2021 Oct 19;10(20):e022453
pubmed: 34622672
Joint Bone Spine. 2020 Oct;87(5):445-448
pubmed: 32251735
Front Cell Dev Biol. 2021 May 04;9:668759
pubmed: 34017836
Kidney Blood Press Res. 2018;43(1):287-295
pubmed: 29490308
Saudi J Biol Sci. 2018 Jul;25(5):849-857
pubmed: 30108431
Lipids Health Dis. 2016 Mar 11;15:54
pubmed: 26968837
Curr Cardiol Rep. 2009 Jan;11(1):21-7
pubmed: 19091171
Endocr Rev. 2020 Aug 1;41(4):
pubmed: 32393961